| Literature DB >> 30186773 |
Huynh T Hop1, Lauren T Arayan1, Tran X N Huy1, Alisha W B Reyes1, Son H Vu1, WonGi Min1, Hu J Lee1, Man H Rhee2, Hong H Chang3, Suk Kim1,3.
Abstract
The cellular oncogene c-Fos (c-Fos) is a component of activator protein 1 (AP1), a master transcriptional regulator of cells. The suppression of c-Fos signaling by siRNA treatment resulted in significant induction of TLR4, which subsequently activates p38 and ERK1/2 mitogen-activated protein kinases (MAPKs) and enhances F-actin polymerization, leading to an increase in B. abortus phagocytosis. During B. abortus infection, c-Fos signaling is induced, which activates the downstream innate-immunity signaling cascade for bacterial clearance. The inhibition of c-Fos signaling led to increased production of interleukin 10 (IL-10), which partially suppressed lysosome-mediated killing, resulting in increased survival of B. abortus inside macrophages. We present evidence of the regulatory role played by the c-Fos pathway in proliferation during B. abortus infection; however, this was independent of the anti-Brucella effect of this pathway. Another finding is the essential contribution of c-Fos/TRAIL to infected-cell necrosis, which is a key event in bacterial dissemination. These data provide the mechanism via which c-Fos participates in host defense mechanisms against Brucella infection and in bacterial dissemination by macrophages.Entities:
Keywords: Brucella abortus; IL-10; MAPKs; TLR-4; c-Fos
Mesh:
Substances:
Year: 2018 PMID: 30186773 PMCID: PMC6110913 DOI: 10.3389/fcimb.2018.00287
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
List of primer sequences of cytokines, c-Fos and cyclin family genes used for qRT-PCR.
| β-actin | 5′-CGCCACCAGTTCGCCATGGA-3′ | 5′-TACAGCCCGGGGAGCATCGT-3 | |
| Interleukin 1β | 5′-CAACCACACAAGTGATATTC-3′ | 5′-GGATCCACACTCTCCAGCTG-3 | |
| Interleukin 6 | 5′-TCCAGTTGCCTTCTTGGGAC-3′ | 5′-GTACTCCAGAAGACCAGAG-3′ | |
| Tumor necrosis factor | 5′-CACAGAAAGCATGATCCGCG-3′ | 5′-CGGCAGAGAGGAGGTTGACT-3′ | |
| Interleukin 10 | 5′-TGGCCCAGAAATCAAGGAGC-3′ | 5′-CAGCAGACTCAATACACACT-3′ | |
| Cellular oncogene Fos | 5′-CAGATCTGTCCGTCTCTAGTG-3′ | 5′-CAGCAGACTGGGTGGGGAGTC-3′ | |
| Cyclin A1 | 5′-GAGAAGAACCTGAGAAGCAGG-3′ | 5′-GGATCCTGGCCAAGCTGAGCT-3′ | |
| Cyclin A2 | 5′-CGCTGCATCAGGAAGACCAAG-3′ | 5′-CCTTAAGAGGAGCAACCCGTC-3′ | |
| Cyclin D1 | 5′-CCGCAAGCATGCACAGACCT-3′ | 5′-GTGGGTTGGAAATGAACTTC-3′ | |
| Cyclin D2 | 5′-GCTCTGTGCGCTACCGACTT-3′ | 5′-CACGCTTCCAGTTGCAATCA-3′ | |
| Cyclin E1 | 5′-CGGACCACAGCAACATGAAAG-3′ | 5′-CAGGGCTGACTGCTATCCTCG-3′ | |
| Cyclin E2 | 5′-CCAGACTCTCCGCAAGAAACC-3′ | 5′-GTTGGCCACCTGTACTGTCTGG-3′ |
List of primer sequences of trafficking regulators and lysosomal enzymes used for qRT-PCR.
| Rab1 | 5′-CCTTCAATAACGTTAAACAGT-3′ | 5′-TAGTCTACTACTTTCTTTGTGG-3′ | |
| Rab5a | 5′-GTACTACCGAGGAGCACAAG-3′ | 5′-AAGCTGTTGTCATCTGCATAG-3′ | |
| Rab5b | 5′-GACTAGCAGAAGTACAGCCAG- 3′ | 5′-CAATGGTGCTTTCCTGGTATTC-3′ | |
| Rab7 | 5′-CCTCTAGGAAGAAAGTGTTGC-3′ | 5′-TTCTTGACCGGCTGTGTCCCA- 3′ | |
| Rab9 | 5′-GCCCATGCAGATTTGGGACAC-3′ | 5′-GCCGGCTTGGGCTTCTTCTGTA-3′ | |
| Rab10 | 5′-GCCGAATGTTACTAGGGAACAAG-3′ | 5′-GCCGCCTCCTCCACTGCTGATA-3′ | |
| Rab11 | 5′-GAGCAGTAGG TGCCTTATTGG-3′ | 5′-GAACTGCCCTGAGATGACGTA-3′ | |
| Rab14 | 5′-GCCGGAGCTACTATAGAGGAGCT-3′ | 5′-GCCGTTCTGATAGATTTTCTTGG-3′ | |
| Rab20 | 5′-CTGCTGCAGCGCTACATGGAGCG- 3′ | 5′-CTCCGCGGCAGTACAGGGAGC-3′ | |
| Rab22a | 5′-GCCGACAAGAACGATTTCGTGCA-3′ | 5′-GCCGACTTCTCTGACATCAGTA-3′ | |
| Rab24 | 5′-GCGCGGGTGAGCACCGCAGGGC-3′ | 5′-GCCTCAGACCCCAACCCCAAG-3′ | |
| Rab31 | 5′-GCCCAGAAAACATTGTGATGGCG-3′ | 5′-GGCATTCTTCGCGCTGGTCTCC-3′ | |
| Rab32 | 5′-GCCGAGTATACTATAAGGAAGCTC-3′ | 5′-GCCCTGGGAAGGACTCTGGCTG-3′ | |
| Rab34 | 5′-GCAAAGTGACCCCGTGTGGCGGG−3′ | 5′-GGGCGTCCCGAAGACCACTCGG-3′ | |
| Early endosome antigen 1 | 5′-GCCCAATGAAGAGTCAGCAAGTC-3′ | 5′-GCCCACCTTGAGATGCTGGCGC-3′ | |
| Rab-interacting lysosomal protein | 5′-CAGGAACAGCTACAGCGCCTCCT-3′ | 5′-CTGAGGTTGCCGCATCAGGTTC-3′ | |
| Lysosomal membrane glycoprotein 1 | 5′-GGCCGCTGCTCCTGCTGCTGCTG- 3′ | 5′-ATATCCTCTTCCAAAAGTAATTG- 3′ | |
| Lysosomal membrane glycoprotein 2 | 5′-AGGGTACTTGCCTTTATGCAGAAT-3′ | 5′-GTGTCGCCTTGTCAGGTACTGC−3′ | |
| Lysozyme 1 | 5′-CTCTCCTGACTCTGGGACTCCTCC-3′ | 5′-CTGAGCTAAACACACCCAGTCAGC-3′ | |
| Lysozyme 2 | 5′-GGCCAAGGTCTACAATCGTTGTG−3′ | 5′-GCAGAGCACTGCAATTGATCCCA−3′ | |
| Hexosaminidase A | 5′-GCCGGCTGCAGGCTCTGGGTTTC- 3′ | 5′-GCGCGGCCGAACTGACATGGTAC- 3′ | |
| Hexosaminidase B | 5′-CCCGGGCTGCTGCTGCTGCAGGC- 3′ | 5′- GTGGAATTGGGACTGTGGTCGATG- 3′ | |
| Hexosaminidase D | 5′-CCACGCCATTTAAGATGAGATTAG-3′ | 5′-GGCCCTCAGCAGCCTCAGGTGGCC-3′ | |
| Galactosidase, α | 5′-GGCCATGAAGCTTTTGAGCAGAG- 3′ | 5′- AGTCAAGGTTGCACATGAAACGTT- 3′ | |
| Galactosidase, β1 | 5′-GGAGGTGCAGCGGCTGGCCAGAGC-3′ | 5′-GGTGACATTATAGATGCCGTGCGC-3′ | |
| Galactosidase, β1 like | 5′-GTGACGGGTGGGAAAGCCCTCACC-3′ | 5′-CTGTCATGTTCCCGATCCACAACG-3′ | |
| Lipoprotein lipase | 5′- CAGACATCGAAAGCAAATTTGCCC-3′ | 5′- GTCCATCCATGGATCACCACGAAG-3′ | |
| Cathepsin A | 5′-GCCCTCCCCGGCCTGGCCAAGCAG-3′ | 5′-GCCGGCTGGATCAGAAAGGGGCCG-3′ | |
| Cathepsin B | 5′-GCCGTGGTGGTCCTTGATCCTTCTT-3′ | 5′-GCCCCTCACCGAACGCAACCCTTC-3′ | |
| Cathepsin C | 5′-GCCGCCACACAGCTATCAGTTACTG-3′ | 5′-GCCCCTGGAGACCTCCAAGATGTGC-3′ | |
| Cathepsin D | 5′-CGTCTTGCTGCTCATTCTCGGCCTC- 3′ | 5′-CACTGGCTCCGTGGTCTTAGGCGAT- 3′ | |
| Cathepsin E | 5′-GGAGCAGAGTGAGAGAGAAGCTAC-3′ | 5′- GGGCCCGTAGTTTCTTCCGAAGGG-3′ | |
| Cathepsin F | 5′-GCC GCA GGC TCC GCC TCG-3′ | 5′-GCC GCT CCT AGC ACG GCC-3′ | |
| Cathepsin G | 5′- CCTGTGCACACCTGTATCTACATAA-3 | 5′- CTGTGTACCGAGTCACCGTACACGC-3′ | |
| Cathepsin H | 5′- CTGAGAACCCTTCTTCCCAAGAGC−3′ | 5′- AGCAGCCAGGCCCCAGCGCACAGC−3′ | |
| Cathepsin K | 5′- GGATGAAATCTCTCGGCGTTTAAT-3′ | 5′- GTCTCCCAAGTGGTTCATGGCCAG-3′ | |
| Cathepsin L | 5′-GCCCCTTTTGGCTGTCCTCTGCTT-3′ | 5′-GCCCTCCATGGAAAAGCCGTGC-3′ | |
| Cathepsin O | 5′-GCCCGCAGTTGGTGAACCTCTTGCT-3′ | 5′-GCCGTCCTTCTGCTGGGTATCTGGG-3′ | |
| Cathepsin S | 5′-GCCGACTACCATTGGGATCTCTGGA-3′ | 5′-GCCGTCTCCCATATCGTTCATGCCC-3′ | |
| Cathepsin Z | 5′- GGCGTCGTCGGGGTCGGTGCAGCA- 3′ | 5′- CTGCGCCCCAGCAGAGCCAGCTG- 3′ |
Figure 1c-Fos controls cell proliferation and bacterial infection via two distinct mechanisms in B. abortus-infected macrophages. (A) RAW 264.7 cells were infected with B. abortus, and the transcriptional profiles of c-fos were examined by qRT-PCR. (B) The activation of c-Fos in B. abortus-infected cells was evaluated by western blotting at different time points. (C) Cells were treated with c-fos siRNA prior to B. abortus infection, and cell proliferation was examined. (D) The transcriptional profiles of proliferative genes were assessed by qRT-PCR at 24 h pi. (E) Flow cytometry histograms and quantitative analysis of B. abortus internalization in c-fos or control siRNA-treated cells at 30 min pi. (F) Flow cytometry histograms and quantitative analysis of intracellular B. abortus growth in c-fos or control siRNA-treated cells at the indicated time points. (G) Flow cytometry histograms and quantitative analysis of intracellular B. abortus growth in ccnd1/ccnd2 or control siRNA-treated cells at the indicated time points. The data represent the mean ± SD of triplicate experiments. The asterisk indicates significant difference (P < 0.05). Abbreviations: ND, not detectable; DK, double knockdown.
Figure 2c-Fos inhibits bacterial uptake by modulating F-actin polymerization and phagocytic signaling. RAW 264.7 cells were treated with c-fos siRNA prior to B. abortus infection. (A) MAPK activation was assessed by western blotting at 30 min pi. (B) F-actin polymerization was observed by fluorescence microscopy at 30 min pi. (C) Flow cytometry histograms and quantitative analysis of F-actin content at 30 min pi. The data represent the mean ± SD of triplicate experiments. The asterisk indicates significant difference (P < 0.05). Scale bars=1 μm.
Figure 3c-Fos mediates TLR-4 signaling to control B. abortus phagocytosis but not intracellular replication. (A) Flow cytometry histogram and quantitative analysis of TLR-4 expression after 2 days of c-fos or control siRNA treatment in RAW 264.7 cells. (B) The expression of TLR-4 was confirmed by fluorescence microscopy and its quantitative analysis in c-fos or control siRNA-treated cells. (C) Flow cytometry histograms and quantitative analysis of B. abortus internalization in cells concomitantly treated with c-fos siRNA and anti-TLR-4 mAb at 30 min pi. (D) The activation of MAPK in cells concomitantly treated with c-fos siRNA and anti-TLR-4 mAb was evaluated by western blotting at 30 min pi. (E) Flow cytometry histograms and quantitative analysis of F-actin content in cells concomitantly treated with c-fos siRNA and anti-TLR-4 mAb at 30 min pi. The data represent the mean ± SD of triplicate experiments. The asterisk indicates significant difference (P < 0.05).
Figure 4c-Fos has both pro- and anti-inflammatory effects during B. abortus infection in RAW264.7 cells. (A) Cells were pretreated with c-fos siRNA before B. abortus infection, and total RNA was isolated. The transcriptional profiles of cytokine genes were evaluated by qRT-PCR. (B) Cytokine production was evaluated by sandwich ELISA. (C) Flow cytometry histograms and (D) Quantitative analysis of intracellular B. abortus growth in cells concomitantly treated with c-fos siRNA and anti-IL-10 mAb. The data represent the mean ± SD of triplicate experiments. The asterisk indicates significant difference (P < 0.05).
Figure 5BCPs fail to recruit lysosomal enzymes in c-Fos-deficient RAW 264.7 cells. Macrophages were treated with c-fos siRNA prior to B. abortus infection. (A) Transcriptional profiles of trafficking regulators were evaluated by qRT-PCR at 2 h pi. (B) Transcriptional profiles of trafficking regulators were evaluated by qRT-PCR at 24 h pi (C) Transcriptional profiles of lysosomal enzymes were evaluated by qRT-PCR at 2 h pi. (D) Transcriptional profiles of lysosomal enzymes were evaluated by qRT-PCR at 24 h pi. (E) The expression of representatives was evaluated by western blotting at 24 h pi. (F) Transcriptional profiles of phagolysosomal genes in cells concomitantly treated with c-fos siRNA and anti-IL-10 mAb were assessed by qRT-PCR at 24 h pi. (G) The colocalization of BCPs with LAMP-1 was analyzed at 2 h pi. (H) The colocalization of BCPs with CtsA and (I) CtsL was analyzed at 24 h pi. Arrow, marker positive; arrow heads, marker negative. The percentage of markers colocalized with BCPs in 100 cells was determined. The data represent the mean ± SD of triplicate experiments. The asterisk indicates significant difference (P < 0.05).
Figure 6The c-Fos/TRAIL pathway controls the outcome of B. abortus infection by governing cell necrosis during late infection. RAW 264.7 macrophages were treated with different siRNAs prior to B. abortus infection and subjected to staining with apopxin green (apoptosis) or 7-AAD (necrosis). (A) Quantitative analysis of the flow cytometry assay for apoptosis and necrosis from 10,000 events at 48 h pi. (B) Cell necrosis was observed by fluorescence microscopy at 48 h pi. (C) Quantitative analysis of the flow cytometry assay for apoptosis and necrosis from 10,000 events at 48 h pi. The data represent the mean ± SD of triplicate experiments. The asterisk indicates significant difference (P < 0.05).